Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T22977
|
||||
| Former ID |
TTDR00265
|
||||
| Target Name |
Superoxide dismutase [Cu-Zn]
|
||||
| Gene Name |
SOD1
|
||||
| Synonyms |
Superoxide dismutase; SOD1
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Dermatitis [ICD9: 692.9; ICD10: L20-L30] | ||||
| Motor neurone disease [ICD9: 335.2; ICD10: G12.2] | |||||
| Neurological disease [ICD9: 338, 338.2, 410, 782.3,780; ICD10: I21, I22, R52, R52.1-R52.2, R60.9, G89] | |||||
| Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
| Function |
Destroys radicals which are normally produced within the cells and which are toxic to biological systems.
|
||||
| BioChemical Class |
Oxidoreductases acting on superoxide as acceptor
|
||||
| UniProt ID | |||||
| EC Number |
EC 1.15.1.1
|
||||
| Sequence |
MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAGCTS
AGPHFNPLSRKHGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCIIGRTLVV HEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQ |
||||
| Structure |
1AZV; 1BA9; 1DSW; 1FUN; 1HL4; 1HL5; 1KMG; 1L3N; 1MFM; 1N18; 1N19; 1OEZ; 1OZT; 1OZU; 1P1V; 1PTZ; 1PU0; 1RK7; 1SOS; 1SPD; 1UXL; 1UXM; 2AF2; 2C9S; 2C9U; 2C9V; 2GBT; 2GBU; 2GBV; 2LU5; 2NNX; 2R27; 2V0A; 2VR6; 2VR7; 2VR8; 2WKO; 2WYT; 2WYZ; 2WZ0; 2WZ5; 2WZ6; 2XJK; 2XJL; 2ZKW; 2ZKX; 2ZKY; 3CQP; 3CQQ; 3ECU; 3ECV; 3ECW; 3GQF; 3GTV; 3GZO; 3GZP; 3GZQ; 3H2P; 3H2Q; 3HFF; 3K91; 3KH3; 3KH4; 3LTV; 3QQD; 3RE0; 3T5W; 4A7G; 4A7Q; 4A7S; 4A7T; 4A7U; 4A7V; 4B3E; 4BCY; 4BCZ; 4BD4; 4FF9; 4MCM; 4MCN; 4NIN; 4NIO; 4NIP; 4OH2; 4SOD; 1AZV; 1BA9; 1DSW; 1FUN; 1HL4; 1HL5; 1KMG; 1L3N; 1MFM; 1N18; 1N19; 1OEZ; 1OZT; 1OZU; 1P1V; 1PTZ; 1PU0; 1RK7; 1SOS; 1SPD; 1UXL; 1UXM; 2AF2; 2C9S; 2C9U; 2C9V; 2GBT; 2GBU; 2GBV; 2LU5; 2NNX; 2R27; 2V0A; 2VR6; 2VR7; 2VR8; 2WKO;2WYT; 2WYZ; 2WZ0; 2WZ5; 2WZ6; 2XJK; 2XJL; 2ZKW; 2ZKX; 2ZKY; 3CQP; 3CQQ; 3ECU; 3ECV; 3ECW; 3GQF; 3GTV; 3GZO; 3GZP; 3GZQ; 3H2P; 3H2Q; 3HFF; 3K91; 3KH3; 3KH4; 3LTV; 3QQD; 3RE0; 3T5W; 4A7G; 4A7Q; 4A7S; 4A7T; 4A7U; 4A7V; 4B3E; 4BCY; 4BCZ; 4BD4; 4FF9; 4MCM; 4MCN; 4NIN; 4NIO; 4NIP; 4OH2; 4SOD
|
||||
| Drugs and Mode of Action | |||||
| Drug(s) | Coprexa | Drug Info | Phase 3 | Neurological disease | [1] |
| ATN-224 | Drug Info | Phase 2 | Solid tumours | [2] | |
| Methoxyestradiol | Drug Info | Phase 2 | Discovery agent | [3] | |
| APN-201 | Drug Info | Phase 1/2 | Dermatitis | [4] | |
| Inhibitor | Acetate Ion | Drug Info | [5] | ||
| ATN-224 | Drug Info | [1] | |||
| Coprexa | Drug Info | [1] | |||
| Methoxyestradiol | Drug Info | [6] | |||
| S-Oxy Cysteine | Drug Info | [7] | |||
| TDI-0107 | Drug Info | [1] | |||
| Modulator | APN-201 | Drug Info | [8] | ||
| TDI-0060 | Drug Info | [1] | |||
| TDI-0079 | Drug Info | [1] | |||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| Pathways | |||||
| BioCyc Pathway | Reactive oxygen species degradation | ||||
| KEGG Pathway | Peroxisome | ||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Huntington' | |||||
| s disease | |||||
| Prion diseases | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| Pathway Interaction Database | Validated nuclear estrogen receptor alpha network | ||||
| FOXA1 transcription factor network | |||||
| PathWhiz Pathway | Degradation of Superoxides | ||||
| Reactome | Platelet degranulation | ||||
| Detoxification of Reactive Oxygen Species | |||||
| WikiPathways | Oxidative Stress | ||||
| Copper homeostasis | |||||
| Detoxification of Reactive Oxygen Species | |||||
| Nifedipine Activity | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Dopamine metabolism | |||||
| AGE/RAGE pathway | |||||
| Folate Metabolism | |||||
| Vitamin B12 Metabolism | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| REF 1 | Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82. | ||||
| REF 2 | ClinicalTrials.gov (NCT00405574) Study of ATN-224 in Patients With Prostate Cancer. U.S. National Institutes of Health. | ||||
| REF 3 | ClinicalTrials.gov (NCT00592579) A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma. U.S. National Institutes of Health. | ||||
| REF 4 | ClinicalTrials.gov (NCT01513278) Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer. U.S. NationalInstitutes of Health. | ||||
| REF 5 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | ||||
| REF 6 | Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor. J Biol Chem. 2003 Jan 3;278(1):407-14. Epub 2002 Oct 29. | ||||
| REF 7 | DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-4. Nucleic Acids Res. 2011 January | ||||
| REF 8 | Peyronie's disease: a critical appraisal of current diagnosis and treatment. Int J Impot Res. 2008 Sep-Oct;20(5):445-59. doi: 10.1038/ijir.2008.30. Epub 2008 Jul 24. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.